Cenix BioScience said this week that its roughly one-year old service contract with Ugichem, a developer of novel gene-silencing therapeutics, has been extended.
Under the extended arrangement, Cenix said it will continue to apply its expertise in combining gene-silencing analyses with high-content screening in cultured cells, to facilitate the characterization and further optimization of Ugichem’s lead compounds. Additional terms were not disclosed.